Related Experiment Video

Updated: May 9, 2026

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

Comorbid depression in heart failure

J Wallenborn1, C E Angermann

  • 1Department of Internal Medicine I, University Hospital and University of Würzburg, Würzburg, Germany.

Herz
|August 1, 2013
PubMed

Insights

Heart failure patients have higher rates of depression, impacting outcomes and costs. While screening is possible, antidepressants haven't improved major clinical endpoints in heart failure.

Area of Science:

  • Cardiology
  • Psychiatry
  • Health Services Research

Background:

  • Heart failure (HF) is a prevalent condition with significant morbidity, mortality, and healthcare costs.
  • Depression is notably more common in HF patients, occurring up to five times more frequently than in the general population.
  • Comorbid depression exacerbates HF outcomes, increasing mortality risk, healthcare expenditures, and diminishing quality of life.

Purpose of the Study:

  • To highlight the increased prevalence of depression in heart failure patients.
  • To discuss the mediators contributing to the adverse effects of comorbid depression in HF.
  • To evaluate the utility of screening tools and the impact of antidepressants on clinical outcomes.

Main Methods:

  • Review of literature on heart failure and comorbid depression.
  • Discussion of potential biological, behavioral, and psychosocial mediators.
  • Assessment of screening instruments like the Patient Health Questionnaire-2 (PHQ-2).
  • Evaluation of the evidence for antidepressant efficacy in HF patients.

Main Results:

  • Depression is highly prevalent in heart failure patients, significantly worsening their prognosis.
  • Biological, behavioral, and psychosocial factors likely mediate the negative impact of depression.
  • Screening tools like the PHQ-2 can identify at-risk individuals.
  • Antidepressants may improve psychological well-being but have not shown benefits for major clinical endpoints in HF.

Conclusions:

  • Depression is a critical comorbidity in heart failure that requires attention.
  • Effective screening for depression in HF patients is feasible.
  • Current evidence does not support the use of antidepressants for improving hard clinical outcomes in heart failure.

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.